Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company focused on optimizing drug delivery, is set to present at the 20th International Symposium on Digestive Endoscopy (ISDE) World Congress for Esophageal Diseases in Edinburgh, Scotland. The presentation, scheduled for September 22-24, 2024, will feature data from cohorts one through four of the RESOLVE trial, highlighting the company’s innovative approach to treating eosinophilic esophagitis (EoE).
Eupraxia’s proprietary DiffuSphereTM technology is a polymer-based micro-sphere platform designed to deliver drugs directly to the targeted tissue, maximizing therapeutic effect while potentially minimizing side effects. This approach offers a significant advantage over traditional drug delivery methods, which often lead to fluctuating drug levels in the body.
The RESOLVE trial, currently in Phase 1b/2a, is evaluating the efficacy and safety of EP-104GI, a drug formulated using the DiffuSphereTM technology, for the treatment of EoE. EP-104GI is administered as an injection directly into the esophageal wall, providing a localized and sustained drug delivery system. This unique approach has the potential to transform the treatment of EoE and offer patients a more effective and well-tolerated therapy.
Eupraxia is not only focused on EoE. The company has also completed a Phase 2b clinical trial (SPRINGBOARD) for EP-104IAR, a drug designed to treat pain caused by knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints, demonstrating the potential of Eupraxia’s technology to address a wide range of conditions.
Eupraxia’s commitment to developing innovative therapies extends beyond these two products. The company is actively building a pipeline of later and earlier-stage long-acting formulations with potential applications in oncology, inflammatory joint conditions, and other critical disease areas. The company’s vision is to utilize the DiffuSphereTM technology to improve the safety, efficacy, and tolerability of existing and novel drugs, ultimately delivering better outcomes for patients worldwide.
